Cabaletta Bio CABA 深 滬
等待開盤 09-18 09:30:00 美东时间
1.92
-0.070
-3.52%
華盛通- 最 高2.11
- 今 開2.02
- 成交量 251.67万股
- 最 低 1.915
- 昨 收 1.99
- 總市值 1.73亿
- 52周最高 5.46
- 市盈率 靜 --
- 換手率 2.80%
- 52周最低 0.9857
- 委 比 -15.14%
- 總股本 8994.31万
- 歷史最高 26.35
- 量 比 1.29
- 振 幅 9.80%
- 歷史最低 0.59
- 每 手 1
- 風險率 6.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $15 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $15 price target.
09-05 21:47
Cabaletta Bio Updates on Rese-cel Therapy Progress
Cabaletta Bio ( ($CABA) ) has shared an announcement. On September 3, 2025, Cab...
09-03 18:28
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio, a biotech company developing targeted cell therapies for autoimmune diseases, will participate in four investor conferences in September 2025. The events include the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, the Morgan Stanley Global Healthcare Conference on September 10, and the H.C. Wainwright Global Investment Conference on the same day. Webcasted fireside chats wil...
08-27 12:00
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
08-11 20:45
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio announced plans to initiate registration cohorts for rese-cel in myositis by late 2025 and anticipates a 2027 BLA submission. Five disease-specific cohorts in the RESET program have completed enrollment, with expansion ongoing across multiple autoimmune diseases. The company also highlighted positive clinical data at the EULAR 2025 Congress, showing significant patient responses without immunomodulators or steroids. Furthermore, the...
08-07 11:30
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
07-30 23:07
Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment
Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical stu...
07-18 00:23
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
06-30 20:36
砍完地产卖金融，雅戈尔拿什么再赚140亿？
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：源媒汇 作者 | 童画 过去十二个月，雅戈尔连续出售了...
06-27 16:36
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
